NCT06500403Recruiting
Non-invasive Tools for PSVD Diagnosis
Noninvasive Tools for the Diagnosis of Porto-sinusoidal Vascular Disease: a Single-center, Prospective, Cohort Study
Source: ClinicalTrials.gov · Last updated 15 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 8 Jul 2024
- Start date
- 28 Feb 2024
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- High blood pressure
- NCT number
- NCT06500403
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 28 Feb 2024 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Underwent liver transplantation;
Other illness
- Complicated with severe heart, kidney, or lung failure;
Other
- Liver pathology suggested cirrhosis;
- Combined with hepatocellular carcinoma exceeding Milan criteria;
- Pregnant or lactating women;
- Data is seriously missing;
- Patients were judged not suitable for participation in this study by the researchers.
Who the study is looking for
- Received platinum chemotherapy for organ tumors;
- Ages 18-80;
- sign the informed consent voluntarily.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang hospital, Southern Medical Uiversity Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.